“It might have benefit but is it worth it?” – Health Economic perspectives on Genomic Medicine.
A limited health care budget coupled with increasing demands raises questions concerning whether a health care system should fund developments in genomic medicine over competing priorities and services, such as public health interventions to reduce inequalities in healthcare, health and social care infrastructure, or introduction of new and often expensive therapies.
Health economics, a discipline concerned with the allocation of precious health care resources, can help inform this debate and provide policy advice. The “Genomic Medicine – Health Economics” satellite workshop will bring together health economists addressing such issues, to present their work on the health economics of genomic medicine. Presentations and discussions will be informative for geneticists, policy makers, clinicians and health economists.